---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-043755"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:46:11.178873+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nektar REZOLVE-AD maintenance data show durable EASI-75/90, vIGA-AD responses

## Summary
- 71% (monthly) and 83% (quarterly) maintained EASI-75 on 24 µg/kg; 85% and 63% maintained vIGA-AD 0/1.
- EASI-100 increased 2-5 fold: from 4% to 22% (monthly) and 9% to 18% (quarterly) in re-randomized patients.
- Discontinuation rate due to AEs was 3.5%; injection site reactions mostly mild; no new safety concerns.
- FDA alignment on Phase 3 design: 24 µg/kg Q2W induction, co-primary endpoints; start Q2 2026.
- New responses at Week 52: 51% new EASI-75 (monthly) and 39% (quarterly) support prolonged therapy.

## SEC filing metadata
- accession: 0001193125-26-043755
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/0001193125-26-043755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/d103279d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-043755
- JSON: https://secwatch.observer/filing/0001193125-26-043755.json
- Plain text: https://secwatch.observer/filing/0001193125-26-043755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.